DDInter93 DDInter1620
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} (Compound) resembles {v} (Compound) Ropivacaine
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Ropivacaine
Anagrelide {u} (Compound) upregulates {v} (Gene) RBM15B
RBM15B {u} (Gene) is upregulated by {v} (Compound) Ropivacaine
Anagrelide {u} (Compound) downregulates {v} (Gene) ATG3
ATG3 {u} (Gene) is downregulated by {v} (Compound) Ropivacaine
Anagrelide {u} (Compound) causes {v} (Side Effect) Ventricular tachycardia
Ventricular tachycardia {u} (Side Effect) is caused by {v} (Compound) Ropivacaine
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lidocaine {u} (Compound) resembles {v} (Compound) Levobupivacaine
Levobupivacaine {u} (Compound) resembles {v} (Compound) Ropivacaine
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} (Compound) resembles {v} (Compound) Ropivacaine
Anagrelide {u} (Compound) upregulates {v} (Gene) RBM15B
RBM15B {u} (Gene) regulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Ropivacaine
Anagrelide {u} (Compound) downregulates {v} (Gene) IFRD2
IFRD2 {u} (Gene) is regulated by {v} (Gene) MLLT11
MLLT11 {u} (Gene) is upregulated by {v} (Compound) Ropivacaine
Anagrelide {u} (Compound) causes {v} (Side Effect) Ventricular tachycardia
Ventricular tachycardia {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} (Compound) resembles {v} (Compound) Ropivacaine
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine (Compound) resembles Ropivacaine (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ropivacaine (Compound)
Anagrelide (Compound) upregulates RBM15B (Gene) and RBM15B (Gene) is upregulated by Ropivacaine (Compound)
Anagrelide (Compound) downregulates ATG3 (Gene) and ATG3 (Gene) is downregulated by Ropivacaine (Compound)
Anagrelide (Compound) causes Ventricular tachycardia (Side Effect) and Ventricular tachycardia (Side Effect) is caused by Ropivacaine (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine (Compound) resembles Levobupivacaine (Compound) and Levobupivacaine (Compound) resembles Ropivacaine (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lidocaine (Compound) and Lidocaine (Compound) resembles Ropivacaine (Compound)
Anagrelide (Compound) upregulates RBM15B (Gene) and RBM15B (Gene) regulates MAL (Gene) and MAL (Gene) is upregulated by Ropivacaine (Compound)
Anagrelide (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is regulated by MLLT11 (Gene) and MLLT11 (Gene) is upregulated by Ropivacaine (Compound)
Anagrelide (Compound) causes Ventricular tachycardia (Side Effect) and Ventricular tachycardia (Side Effect) is caused by Lidocaine (Compound) and Lidocaine (Compound) resembles Ropivacaine (Compound)